Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.36 | N/A | +5.29% |
management commentary, guidance changes, and full analysis available with Pro.
| +5.29% |
Tone: Cautiously Optimistic
Overall, management expressed confidence in their current strategies and emphasized the importance of their product pipeline. They remain focused on delivering value to patients and shareholders.
Management highlighted strong performance in key therapeutic areas.
They noted ongoing investments in innovation and pipeline development.
Amgen's earnings report shows a positive surprise in EPS, indicating better-than-expected profitability. The stock's slight increase of 0.64% reflects investor confidence in the company's performance and future prospects, despite the lack of revenue data and guidance. The management's focus on innovation and pipeline development suggests a commitment to long-term growth.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
REGENERON PHARMACEUT
Feb 4, 2022